Hostname: page-component-848d4c4894-sjtt6 Total loading time: 0 Render date: 2024-06-19T08:18:03.203Z Has data issue: false hasContentIssue false
  • English
  • Français

Associations between Carbapenem Use, Carbapenem-Resistant Pseudomonas aeruginosa, and Carbapenem-Resistant Acinetobacter baumannii

Part of: BARRY FARR AWARD RECIPIENTS

Published online by Cambridge University Press:  02 January 2015

Anucha Apisarnthanarak ,
Sumana Jitpokasem  and
Linda M. Mundy
Anucha Apisarnthanarak*
Affiliation:
Division of Infectious Diseases and Infection Control, Faculty of Medicine, Thammasat University Hospital, Pathumthani, Thailand
Sumana Jitpokasem
Affiliation:
Division of Infectious Diseases and Infection Control, Faculty of Medicine, Thammasat University Hospital, Pathumthani, Thailand
Linda M. Mundy
Affiliation:
Bryn Mawr, Pennsylvania
*
Division of Infectious Diseases, Faculty of Medicine, Thammasat University Hospital, Pathumthani, Thailand 12120 (anapisarn@yahoo.com)
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Letters to the Editor
Information
Infection Control & Hospital Epidemiology , Volume 34 , Issue 11 , November 2013 , pp. 1235 - 1237
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2013

References

1.Kollef, MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis 2008;47(suppl 1):S3–S13.Google Scholar
2.Osmon, S, Ward, S, Fraser, VJ, Kollef, MH. Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa. Chest 2004;125:607–616.Google Scholar
3.Sakyo, S, Tornita, H, Tanimoto, K, Fujimoto, S, Ike, Y. Potency of carbapenems for the prevention of carbapenem-resistant mutants of Pseudomonas aeruginosa: the high potency of a new carba-penem doripenem. J Antibiot 2006;59:220–228.CrossRefGoogle Scholar
4.Apisarnthanarak, A, Kiratisin, P, Apisarnthanarak, P, Mundy, LM. Gastrointestinal selective capacity of doripenem, meropenem, and imipenem for carbapenem-resistant gram-negative bacilli in treated patients with pneumonia. Infect Control Hosp Epidemiol 2011;32:410–411.Google Scholar
5.Apisarnthanarak, A, Rujanavech, S, Luxamesathaporn, P, Mundy, LM. Intensified infection control measures to minimize the spread of colistin-resistant Acinetobacter baumannii. Infect Control Hosp Epidemiol 2013;34:445–447.Google Scholar
6.Karageorgopoulos, DE, Falagas, ME. Current control and treatment of multidrug-resistant Acinetobacter baumannii infections. Lancet Infect Dis 2008;8;751-762.Google Scholar
7.Society for Healthcare Epidemiology of America, Infectious Diseases Society of America, Pediatric Infectious Diseases Society. Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS). Infect Control Hosp Epidemiol 2012;33:322–327.Google Scholar